Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery

Size: px
Start display at page:

Download "Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery"

Transcription

1 Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc Riquet, MD; Pierre-Yves Brichon, MD; and the Groupe Thorax Objectives: Published series on the synchronous combined resection of brain metastases and primary non-small cell lung cancer are small and scarce. We therefore undertook a multicenter retrospective study to determine long-term survival and identify potential prognostic factors. Design: Our series includes 103 patients who were operated on between 1985 and 1998 for the following tumors: adenocarcinomas (74); squamous cell carcinomas (20); and large cell carcinomas (9). Three patients had two brain metastases, and one patient had three metastases; the remaining patients had a single metastasis. Ninety-three patients presented with neurologic signs that regressed completely after resection in 60 patients and partially, in 26 patients. Neurosurgical resection was incomplete in six patients. Seventy-five patients received postoperative brain radiotherapy. The time interval between the brain operation and the lung resection was < 4 months. Pulmonary resection was incomplete in eight patients. Results: The survival calculated from the date of the first operation was 56% at 1 year, 28% at 2 years, and 11% at 5 years. Univariate analysis showed a better prognosis for adenocarcinomas (p 0.019) and a trend toward a better prognosis for patients with small pulmonary tumors (T1 vs T3, p 0.068), N0 stage disease (N0 vs N, p 0.069), and complete pulmonary resection (p 0.057). In a multivariate analysis, adenocarcinoma histology also affected the survival rate (p 0.03). Conclusions: It seems legitimate to proceed with lung resection after complete resection of a single brain metastasis, at least in patients with an adenocarcinoma and a small lung tumor and without abnormal mediastinal lymph nodes seen on the CT scan or during mediastinoscopy. (CHEST 2001; 119: ) Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery Abbreviations: NSCLC non-small cell lung cancer; WBRT whole-brain radiotherapy Bronchogenic carcinoma is the cancer that most commonly metastasizes to the brain and accounts for 50% of brain metastases. 1 Unfortunately, once metastatic brain disease develops, the cancer has already widely disseminated. 2 Seven percent of *From the Department of Thoracic Surgery (Drs. Bonnette and Puyo) and the Department of Statistics (Dr. Gabriel), Hôpital Foch, Suresnes, France; the Department of Thoracic Surgery (Dr. Giudicelli), Hôpital Ste-Marguerite, Marseille, France; the Department of Thoracic Surgery (Dr. Regnard), Hôpital Marie Lannelongue, Le Plessis-Robinson, France; the Department of Thoracic Surgery (Dr. Riquet), Hôpital Laënnec, Paris, France; and the Department of Thoracic Surgery (Dr. Brichon), Hôpital La Tronche, Grenoble, France. A complete list of Groupe Thorax investigators and participating centers is located in the Appendix. Manuscript received June 27, 2000; revision accepted November 15, Correspondence to: Pierre Bonnette, MD, Service de Chirurgie Thoracique, Hôpital Foch, BP 36, 40 rue Worth, Suresnes, France; pierre.bonnette@wanadoo.fr patients present with neurologic symptoms pointing to the presence of a solitary brain metastasis from bronchial cancer. 3 Patients with brain metastases from non-small cell lung cancer (NSCLC) have a poor prognoses. Treatment modalities include corticosteroids, chemotherapy, external-beam radiotherapy, stereotactic radiosurgery, or neurosurgery. Combined neurosurgical resection and radiotherapy usually leads to rapid and lasting regression of symptoms and may prolong survival by decreasing neurologic morbidity and mortality. 4,5 According to Patchell et al, 4 25% of patients with a single brain metastasis from various primary tumor sites would benefit from curative neurosurgery. If the decision to resect a single brain metastasis revealing a NSCLC may be readily taken, resection of the primary lung tumor is more controversial. 6 CHEST / 119 / 5/ MAY,

2 Many articles 7 11 reporting the results of series with patients who have undergone dual resection have been published, and some have reported extended survival 12 ( 10 years). Such series, however, are small and date back some years. In light of these facts, we undertook a multicenter retrospective study to determine the long-term survival time, to identify potential prognostic factors, and to define the indications for adjuvant treatment after synchronous resection of brain metastasis and primary lung cancer. Patient Characteristics Materials and Methods A questionnaire was sent to the members of the Groupe Thorax, a group of French thoracic surgeons, to collect data on all patients who had undergone surgery between January 1985 and December At that time, standard investigations included at least a CT scan of the chest, a CT scan or MRI scan of the brain, and a CT scan or ultrasound of the abdomen. Isotope bone scans were not routinely performed. The operations were to have been performed 4 months apart. Tumor histology had to be that of a squamous carcinoma, an adenocarcinoma, or a large cell lung cancer. Thirteen surgical centers (see Appendix ) responded and provided data for 103 patients. Four teams had operated on 16 patients. Patients included 89 men and 14 women. The mean age was 54 years, with a range of 32 to 85 years. Histology showed 74 adenocarcinomas (including one bronchioloalveolar carcinoma), 20 squamous cell carcinomas, and 9 large cell lung cancers. Ninety-four patients had undergone neurosurgery first (nine of these patients had no neurologic signs, and their brain metastases had been discovered in the course of lung cancer localization studies). Nine patients had undergone thoracic surgery first. The time between the two operations was 30 days for 36 patients, between 31 and 60 days for 36 patients, between 61 and 90 days for 22 patients, and between 91 and 120 days for 9 patients. Among the last nine patients, seven presented with neurologic signs warranting neurosurgery before thoracic surgery, and two developed neurologic signs during the immediate postoperative period after lung surgery. The mean time between the two operations was 46.2 days (46 days when neurosurgery was performed first and 47.7 days when lung surgery was performed first). Forty-one patients received the following perioperative chemotherapy: 6 patients received one or two courses of chemotherapy before any surgery; another 6 patients received one to four courses of chemotherapy between the two operations; and 31 patients received chemotherapy after the second operation (1 patient received four courses between the two operations and four courses after the second operation, and 1 patient received two courses before the first operation and four courses after the second operation). Neurosurgical Aspects Ninety-three patients had neurologic signs before neurosurgical resection, as follows: motor deficit (35 patients); intracranial hypertension (18 patients); convulsions (17 patients); headaches (14 patients); cerebellar syndrome (10 patients); and miscellaneous other signs (9 patients). Some patients had more than one neurologic sign. A single metastasis was found in 99 patients, two metastases were found in 3 patients, and three metastases were found in 1 patient. Complete neurosurgical resection was achieved in 97 patients, and resection was incomplete in 6 patients (2 of whom were among the 4 patients with several metastases). The site of the metastases was supratentorial in 84 patients, infratentorial in 16 patients, both supratentorial and infratentorial in 2 patients (among the 4 patients with several metastases), and unspecified in 1 patient. Postoperative recovery was generally uncomplicated, no patient died and one patient developed postoperative adrenal failure. After surgery, a complete regression of signs was achieved in 60 patients and incomplete regression was achieved in 26 patients; neurologic signs persisted in 6 patients and worsened in 1 patient. Seventy-five patients received brain radiotherapy, and 26 did not; information on radiotherapy was missing for two patients. When a radiotherapy dose was provided, it ranged from 20 to 50 Gy; however, the specific technique was not described and may have been simple radiotherapy to the resection site, whole-brain radiotherapy (WBRT), or WBRT with a booster dose to the resection site. Thoracic Aspects Sixty-nine patients underwent lobectomies, 25 underwent pneumonectomies, 2 had segmentectomies, and 7 had wedgeresection. Chest wall resection was required in four patients. Resection remained incomplete in eight patients. Two patients died, one after pulmonary artery suture rupture 10 days after undergoing a lobectomy, and the other of a pulmonary embolism 36 days after undergoing a pneumonectomy. Morbidity was observed in five patients and included one postpneumonectomy fistula, one postpneumonectomy empyema, one serious pulmonary infection after pneumonectomy, one pulmonary abscess after lobectomy, and one case of acute ischemia of a limb. Lung tumor staging is given in Table 1. Thirty-three patients, including 3 patients with stage N0 and 30 patients with stage N disease, received radiotherapy to the thorax. When the radiotherapy dose was indicated, it ranged between 45 and 55 Gy. Methods This was a multicenter retrospective study. Participating surgeons were asked to provide data on tumor recurrence sites and on the cause of death. However, the primary survival data often were obtained from the vital statistics department. Survival time was calculated from the date of the first operation. Survival curves were calculated using the nonparametric Kaplan-Meier method. 13 Univariate comparison of survival was carried out by log-rank analysis, 14 and multivariate analysis was performed using the Cox proportional hazards model. 15 Table 1 Staging of the Primary Pulmonary Tumor* Stage *? status unknown. Patients, No. T1 23 T2 61 T3 16 T4 2 T? 1 N0 40 N1 23 N2 35 N3 1 N? Clinical Investigations

3 Results No patient died after undergoing a craniotomy. Two deaths occurred 10 and 36 days after thoracotomies. Seven patients were lost to follow-up but were not known to have recurrences, and 15 patients, including 1 with a brain recurrence, were still alive at the time of the study (October 1999). The mean length of follow-up was 17.3 months. Two patients died of intercurrent causes. Forty-five patients had brain recurrences, which was single in 22 patients and was associated with other localizations in the remaining 23 patients (7 thoracic sites and 18 other sites). Nineteen of these 45 patients (42%) had not received brain radiotherapy. In many cases, it was impossible to determine whether the recurrence was at the same site as the first metastasis or elsewhere in the brain. Only 14 patients developed a thoracic recurrence (ipsilateral, contralateral, mediastinal, pleural, etc), which was a single recurrence in 2 patients, was associated with a brain recurrence in 7 patients, and was associated with distant metastases in 5 patients. Nineteen patients had tumor dissemination with no brain and/or thoracic recurrence. The four patients who were operated on with two or three brain metastases died after 12, 13, 15, and 32 months. The calculated survival rate (Kaplan-Meier method) for the 103 patients was 56% at 1 year, 28% at 2 years, 13% at 3 years, and 11% at 5 years (Fig 1). The median length of survival was 12.4 months. Univariate analysis was used to identify potential predictive factors. Histology was found to affect survival. Patients with adenocarcinomas had a better prognosis than those with squamous cell carcinomas (p 0.019) [Fig 2]. Survival curves drawn on the Figure 2. Survival time of patients with primary adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Patients with adenocarcinomas had a significantly prolonged survival time (p 0.019). basis of the T staging of the pulmonary tumor seemed to show a decrease in survival time from stage T1 to stages T2 and T3, but the difference was not significant, even between stages T1 and T3 (p 0.068) (Fig 3). Similarly, the survival curve for stage N0 tumors (n 40) seemed better than for that for stage N tumors (n 59), but the difference was not significant (p 0.069) (Fig 4). The difference between complete lung resection (n 95) and incomplete lung resection (n 8) was not significant (p 0.057) [Fig 5]. Furthermore, there was no significant difference between complete and incomplete neurosurgical resection, between brain radiotherapy and no radiotherapy, between radiotherapy to the chest or no radiotherapy, between men and women, between Figure 1. Overall survival time from the time of the first procedure in 103 patients undergoing resections of brain metastases and primary lung cancer. Figure 3. Survival time according to the T status of the primary lung cancer. Survival tended to be shorter in patients with later T stages, but the difference did not achieve significance. CHEST / 119 / 5/ MAY,

4 Figure 4. Survival time according to the N status of the primary lung cancer. Survival time tended to be shorter in patients with later N stage, but the difference did not achieve significance. supratentorial or infratentorial resection, and between chemotherapy or no chemotherapy (p 0.13). Multivariate analysis of these data using the Cox proportional hazards model to clarify the independent roles of histology, locoregional staging, chemotherapy, and complete pulmonary resection showed that complete resection (p 0.52), the T (p 0.14) and N (p 0.12) staging, and chemotherapy (p 0.07) did not significantly affect survival time but that adenocarcinoma histology did (p 0.03). Discussion The diagnosis of synchronous lung cancer and a single metastasis usually rules out surgical resection as a therapeutic option. Small series 16,17 of the resection of both lung cancer and adrenal metastases have been published. Several larger series with brain metastases have been published Our study provides one of the largest series reported in the literature. Because the first patients were operated on in 1985, all patients were investigated with a CT scan of the thorax and a CT scan or an ultrasound of the abdomen. Brain investigations used a CT scan or MRI scan, but we do not know how many patients had MRI scans. Schellinger et al 18 reported that among the 55 patients showing a solitary brain metastasis on the CT scan, 17 (31%) showed multiple metastases on the MRI scan. It is therefore essential to obtain an MRI scan before proceeding with the resection of a brain metastasis. Most of our patients had neurologic signs. External beam radiotherapy may alleviate symptoms and prolong the median survival time. However, neurosurgery remains an important therapeutic option in selected patients with a single superficial metastasis. Two randomized trials by Patchell et al 4 and Vecht et al 5 concluded that the addition of surgery before radiotherapy increased survival time and improved neurologic function and quality of life compared with radiotherapy alone in patients with a single metastatic brain tumor (Table 2). Yet, in a multicenter randomized trial, Mintz et al 19 failed to detect a difference in survival or quality of life between patients who underwent surgery plus radiotherapy and those who received radiotherapy alone. The patients included in that trial, however, had a low baseline median Karnofsky performance score, and many had extracranial metastases. These differences may explain why no survival benefit was derived from surgical removal. Brain recurrences remain common after neurosurgical resection of a brain metastasis (44% in our series). They may be either local (at the site of the original tumor) or distant (elsewhere in the brain). In a randomized trial, Patchell et al 20 observed that the rate of tumor recurrence in the brain was significantly lower when patients received postoperative WBRT (18% vs 70%; p 0.001). This benefit was apparent for both local (10% vs 46%; p 0.001) and distant recurrences (14% vs 37%; p 0.01), but no statistically significant difference was observed in the median survival time (48 vs 43 weeks; p 0.39). In our series, the postoperative brain radiotherapy provided to 75% of the patients did not affect survival time; however, 42% of the patients with a brain recurrence received no radiotherapy. Nevertheless, WBRT can be associated with significant short-term and delayed toxicity. Figure 5. Survival time in patients who had locoregional primary disease, whether or not resection was complete. The survival time tended to be shorter in patients who had undergone incomplete resections (p 0.057) Clinical Investigations

5 Table 2 Survival Time for Patients With a Single Brain Metastasis from Various Primary Cancers in Trials of Radiation Alone vs Surgery Plus Radiation* Study/Year Subjects, No. Radiation Alone, mo Surgery and Radiation, mo p Value Patchell et al 4 / Vecht et al 5 / Mintz et al 19 / *Values given as median, unless otherwise indicated. Stereotactic radiosurgery also is used to treat a single brain metastasis. The hospital stay is short, and the response on symptoms is slower than with neurosurgery. WBRT is often given at the same time. This treatment modality is reserved for tumors measuring 3 cm and is recommended for deep lesions. In the absence of any randomized study comparing radiosurgery and surgery, opinions diverge on the quality of local tumor control and the place of radiosurgery when neurosurgical resection is feasible. 21,22 In several retrospective studies, 9,23 univariate analysis has shown improved survival times when both the primary lung tumor and brain metastases are resected, whether lung surgery is performed long before neurosurgery (metachronous presentation) or at the same time (synchronous presentation). In a series of 113 patients reported by Harpole et al, 23 brain lesions were treated by either neurosurgical resection (n 52) or stereotactic radiosurgery (n 61) and WBRT. The median survival time was 11 months. A significant benefit was observed for patients who underwent complete lung tumor resection (n 86; median survival time, 16 months; p 0.001), had negative lymph nodes (n 50; median survival time, 18 months; p 0.01), or had stage I or II lung lesions (n 56; median survival time, 18 months; p 0.004). the number of metastases, the histology, the timing of surgery (metachronous, 60 patients; synchronous, 53 patients), or the treatment modality of the brain lesions did not affect survival time. The nodal stage was the only significant factor in a multivariate analysis. Synchronous brain and lung resection series are generally very small (Table 3). Torre et al 7 published a report on a series of 27 patients, of whom 21 underwent synchronous surgery. The overall 5-year survival rate was 15%, and the mean survival time was 26 months. Better results were obtained in patients without node metastases at the time they underwent thoracotomy and in patients with supratentorial metastases. Rossi et al 8 reported on a series of 40 patients who had bifocal resection. The 1-year survival rate was 35%, the 2-year survival rate was 25%, and the 5-year survival rate was 12.5%. All patients surviving for 2 years had a Karnofsky index score of 50 and stage N0 disease after staging. In a series of 185 consecutive patients undergoing resection of brain metastases, Burt et al 9 analyzed 65 patients with synchronous brain metastases (diagnosed 60 days after the primary NSCLC). The 32 patients who underwent complete lung resections had survival rates of 71%, 16%, and 16% at 1, 5, and 10 years, respectively (median survival time, 21 months), compared with survival rates of 40%, 4%, and 0% at 1, 5, and 10 years, respectively, for patients who did not have complete resections (median survival time, 10 months). Multivariate analysis demonstrated that locoregional stage had no significant effect on survival time (p 0.97) but that complete resection of the primary disease significantly prolonged survival time (p 0.002). Mussi et al 10 reported on a series of 45 patients who underwent bifocal resections. The 5-year survival rate for the 15 patients with synchronous presentation was 6.6% with a median survival of 18 months; 14 of these patients died within 30 months. Table 3 Results of Combined Surgery in Some Series Survival Rate, % Study Years of Study Subjects, No. 1 year 2 years 5 years Torre et al Rossi et al 8 Not specified Burt et al Mussi et al Present series CHEST / 119 / 5/ MAY,

6 Only one patient survived for 5 years (survival time, 63 months). The only variable that was significantly associated with a longer survival time was a squamous lung cancer histology (p 0.02). Our series was a multicenter, retrospective series, so that patient management may have varied from one center to another. The large sample allows for the multifactorial analysis of parameters that may have affected survival. All patients underwent modern radiologic investigations. The difference in survival time between patients with stages N0 and N tumors appears to be less obvious in our series (the difference was not significant) than in the other series 7,8,10 in which authors often advise performing a mediastinoscopy and reserving lung resection for patients with stage N0 tumors. In France, for the last 15 years, many patients with a clinical N2 staging on CT scans were operated on without mediastinoscopy, and we do not know in our series how many patients had clinical N0 or N2 staging and how many patients were operated on after negative results of a mediastinoscopy. The better prognosis for patients with adenocarcinomas that was observed in our series also was found by Burt et al 9 but without a significant difference. Age often is considered to be a prognostic factor, 8 but this was not the case in our series. Last, chemotherapy failed to show any benefit. However, patient management has evolved since the first patients in our series were treated (1985). New drugs have been developed, 24 and more is known about drug penetration into the brain, which allows us to hope for more effective chemotherapy, whether it is neoadjuvant, intercurrent (between the two operations), or adjuvant after combined surgery. Conclusion In the absence of any randomized, comparative study, combined surgery on brain metastases and the primary lung tumor seems to prolong survival time. In our series, factors such as the size of the lung tumor and lymph node status affected prognosis to a certain extent. Adenocarcinoma is a favorable prognostic factor in our study, as opposed to other published series. It seems legitimate to proceed with lung resection after complete resection of a single brain metastasis, at least in patients with a small lung tumor and no abnormal mediastinal lymph nodes seen on the CT scan or during mediastinoscopy. Brain radiotherapy is usually advisable to reduce the risk of local recurrences. The value and timing of chemotherapy remain to be defined (neoadjuvant, intercurrent, or adjuvant after the resection of both sites). Appendix The following Groupe Thorax investigators and centers in France participated in the study: F. Bellenot, MD (Argenteuil); P. Bonnette, MD (Suresnes); P.Y. Brichon, MD (Grenoble); M. Dahan, MD (Toulouse); A. Dujon, MD (Rouen); J.M. Faillon, MD (Lille); R. Giudicelli, MD (Marseille); G. Grosdidier, MD (Nancy); A. Joyeux, MD (Nîmes); M. Monteau, MD (Reims); J.F. Regnard, MD (Le Plessis-Robinson); M. Riquet, MD (Laënnec); and D. Van Raemdonck, MD (Leuven). References 1 Walker AE, Robins M, Weinfield FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985; 35: Arbit E, Wronski M. Clinical decision making in brain metastases. Neurosurg Clin North Am 1996; 7: Albain KS. Survival determinants in extensive stage non-small cell lung cancer: the Southwestern Oncology Group. J Clin Oncol 1991; 9: Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: Vecht CJ, Haaxma-Reiche H, Noordijk E, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 1993; 33: Martini N. Rationale for surgical treatment of brain metastasis in non-small cell lung cancer. Ann Thorac Surg 1986; 42: Torre M, Barbieri B, Bera E, et al. Surgical therapy in lung cancer with single brain metastasis. Eur J Cardiothorac Surg 1988; 2: Rossi N, Zavala D, VanGilder J. A combined surgical approach to non-oat-cell pulmonary carcinoma with single cerebral metastasis. Respiration 1987; 51: Burt M, Wronski M, Arbit E, et al. Resection of brain metastases from non-small-cell lung carcinoma. Thorac Cardiovasc Surg 1992; 103: Mussi A, Pistolesi M, Lucchi M, et al. Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. Thorac Cardiovasc Surg 1996; 112: Magilligan DJ, Duvernoy C, Malik G, et al. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years experience. Ann Thorac Surg 1986; 42: Shahidi H, Kvale PA. Long-term survival after surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 1996; 109: Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: Peto R, Pike ML, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient: II. Analysis and examples. Br J Cancer 1977; 35: Porte HL, Roumilhac D, Graziana JP, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 1998; 65: Brichon PY. Resultat de l exerese des metastases surrenaliennes des cancers broncho-pulmonaires operes. Rev Mal Respir 2000; 17(suppl):S Clinical Investigations

7 18 Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44: Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78: Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280: Sawaya R. Intracranial metastatic tumor management: surgical treatment of brain metastases. Clin Neurosurg 1999; 45: Alexander E, Loeffler JS. Intracranial metastatic tumor management: the case for radiosurgery. Clin Neurosurg 1999; 45: Harpole D, Amos A, Alexander E, et al. Stage of the primary is important when treating isolated brain metastases from lung cancer. Proc Am Soc Clin Oncol Annu Meet 1996; 15:A Bunn PA, Kelly K. New combinations in the treatment of lung cancer. Chest 2000; 117:138S 143S 3 rd ACCP SCCM Combined Critical Care Course August Orlando World Center Marriott CHEST / 119 / 5/ MAY,

Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment q

Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment q European Journal of Cardio-thoracic Surgery 25 (2004) 1107 1113 www.elsevier.com/locate/ejcts Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis

Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis 1998 Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis Chaosu Hu, M.D. 1 Eric L. Chang, M.D. 2 Samuel J. Hassenbusch III, M.D., Ph.D. 3 Pamela K. Allen, Ph.D. 2 Shiao Y. Woo,

More information

Adrenal glands are a common metastatic site for non small cell lung cancer

Adrenal glands are a common metastatic site for non small cell lung cancer Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,

More information

Surgical treatment of primary lung cancer with synchronous brain metastases

Surgical treatment of primary lung cancer with synchronous brain metastases General Thoracic Surgery CHD GTS ACD GTS CSP TX Surgical treatment of primary lung cancer with synchronous brain metastases Peter S. Billing, MD Daniel L. Miller, MD Mark S. Allen, MD Claude Deschamps,

More information

Chirurgie beim oligo-metastatischen NSCLC

Chirurgie beim oligo-metastatischen NSCLC 24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Stage III non small cell lung cancer and metachronous brain metastases

Stage III non small cell lung cancer and metachronous brain metastases General Thoracic Surgery Stage III non small cell lung cancer and metachronous brain metastases Nader Moazami, MD a Thomas W. Rice, MD a Lisa A. Rybicki, MS b David J. Adelstein, MD c Sudish C. Murthy,

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François

More information

Treatment of oligometastatic NSCLC

Treatment of oligometastatic NSCLC Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases

Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases ORIGIL ARTICLE Brain Tumor Res Treat 2013;1:64-70 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.

sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ. 1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,

More information

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival The Harvard community has made this article openly

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566

More information

Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex

Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):111-115 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.111 Neurological Change after Gamma Knife Radiosurgery for Brain Metastases

More information

Management of single brain metastasis: a practice guideline

Management of single brain metastasis: a practice guideline PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease

More information

Carcinoma of the Lung

Carcinoma of the Lung THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons

24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons Surgical Management of Lung Cancer with Solitary Cerebral Metastasis John R. Hankins, M.D., John E. Miller, M.D., Michael Salcman, M.D., Frank Ferraro, M.D., David C. Green, M.D., Safuh Attar, M.D., and

More information

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited Original Article Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited Jun Sato 1,2, Hidehito Horinouchi 1, Yasushi Goto 1, Shintaro

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,

More information

and Strength of Recommendations

and Strength of Recommendations ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Small cell lung cancer (SCLC), which represents 20%

Small cell lung cancer (SCLC), which represents 20% ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,

More information

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

Pulmonary Resection for Metastases from Colorectal Cancer

Pulmonary Resection for Metastases from Colorectal Cancer ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,

More information

Selecting the Optimal Treatment for Brain Metastases

Selecting the Optimal Treatment for Brain Metastases Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,

More information

P sumed to have early lung disease with a favorable

P sumed to have early lung disease with a favorable Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Nonsurgical treatment of solitary adrenal metastases

Nonsurgical treatment of solitary adrenal metastases Resection of Adrenal Metastases From Non-Small Cell Lung Cancer: A Multicenter Study Henri Porte, MD, PhD, Joëlle Siat, MD, Benoit Guibert, MD, Francoise Lepimpec-Barthes, MD, René Jancovici, MD, Alain

More information

Br a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases.

Br a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 111:825 831, 2009 The results of resection after stereotactic radiosurgery for brain metastases Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o l k a, M.D.,

More information

Adam J. Hansen, MD UHC Thoracic Surgery

Adam J. Hansen, MD UHC Thoracic Surgery Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered

More information

Multifocal Lung Cancer

Multifocal Lung Cancer Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Laboratory data from the 1970s first showed that malignant melanoma

Laboratory data from the 1970s first showed that malignant melanoma 2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.

More information

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,

More information

The Role of Radiation Therapy

The Role of Radiation Therapy The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative

More information

Lung cancer is a leading cause of cancer death. Approximately

Lung cancer is a leading cause of cancer death. Approximately ORIGINAL ARTICLE Does Initial Staging or Tumor Histology Better Identify Asymptomatic Brain Metastases in Patients with Non small Cell Lung Cancer? Ann A. Shi, MD,* Subba R. Digumarthy, MD,* Jennifer S.

More information

Place of surgery in diagnos1c and therapeu1c strategies: New challenges

Place of surgery in diagnos1c and therapeu1c strategies: New challenges Place of surgery in diagnos1c and therapeu1c strategies: New challenges Philippe Métellus M.D., Ph.D. Department of Neurosurgery, CHU Timone, Marseille, France Place of surgery in diagnos1c and therapeu1c

More information

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D. The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma. Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest

More information

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in 1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the

More information

surgical treatment of brain metastases from lung cancer NARAYAN SUNDARESAN, M.D., JOSEPH H. GALIC1CH, M.D., AND EDWARD J. BEATTIE, JR., M.D.

surgical treatment of brain metastases from lung cancer NARAYAN SUNDARESAN, M.D., JOSEPH H. GALIC1CH, M.D., AND EDWARD J. BEATTIE, JR., M.D. J Neurosurg 58:666-671, 1983 Surgical treatment of brain metastases from lung cancer NARAYAN SUNDARESAN, M.D., JOSEPH H. GALC1CH, M.D., AND EDWARD J. BEATTE, JR., M.D. Neurosurgery and Thoracic Services,

More information

Tumour size as a prognostic factor after resection of lung carcinoma

Tumour size as a prognostic factor after resection of lung carcinoma Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry

More information

M expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment

M expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Surgical treatment of multiple brain metastases

Surgical treatment of multiple brain metastases J Neurosurg 79:210-216, 1993 Surgical treatment of multiple brain metastases RAJESH K. BINDAL, B.A., RAYMOND SAWAYA, M.D., MILAM E. LEAVENS, M.D., ANO J. JACK LEE, PH.D. Departments of Neurosurgery and

More information

We have previously reported good clinical results

We have previously reported good clinical results J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional

More information

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No

More information

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Clinton D. Kemp, MD,* R. Taylor Ripley, MD,* Aarti Mathur, MD, Seth M. Steinberg, PhD, Dao M. Nguyen,

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental

More information

N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.

N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S. N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

Induction chemotherapy followed by surgical resection

Induction chemotherapy followed by surgical resection Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser

More information

Factors influencing survival in patients with breast cancer and single or solitary brain metastasis

Factors influencing survival in patients with breast cancer and single or solitary brain metastasis Factors influencing survival in patients with breast cancer and single or solitary brain metastasis A. Niwińska, K. Pogoda, M. Murawska, P. Niwiński To cite this version: A. Niwińska, K. Pogoda, M. Murawska,

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer

Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer Interactive CardioVascular and Thoracic Surgery 24 (2017) 1 7 doi:10.1093/icvts/ivw321 Advance Access publication 23 September 2016 ORIGINAL ARTICLE Cite this article as: Gao X-L, Zhang K-W, Tang M-B,

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Patients with Single Brain Metastasis from Non-Small Cell Lung Cancer Equally Benefit from Stereotactic Radiosurgery and Surgery: A Systematic Review

Patients with Single Brain Metastasis from Non-Small Cell Lung Cancer Equally Benefit from Stereotactic Radiosurgery and Surgery: A Systematic Review e-issn 1643-3750 DOI: 10.12659/MSM.892405 Received: 2014.09.05 Accepted: 2014.09.23 Published: 2015.01.12 Patients with Single Brain Metastasis from Non-Small Cell Lung Cancer Equally Benefit from Stereotactic

More information

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

Pneumonectomy After Induction Rx: Is it Safe?

Pneumonectomy After Induction Rx: Is it Safe? Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction

More information

PET/CT in lung cancer

PET/CT in lung cancer PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of

More information

Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital

Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,

More information

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Charles Mulligan, MD, FACS, FCCP 26 March 2015 Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening

More information

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14 Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related

More information

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13 Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

SYNOPSIS PROTOCOL N UC-0107/1602

SYNOPSIS PROTOCOL N UC-0107/1602 SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk

More information

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic

More information